Indications for the peptide enhanced bone graft now include single-level anterior cervical discectomy fusion with an allograft bone ring. It can also be used in conjunction with a PEEK titanium alloy or fusion device that has been cleared by the FDA for cervical spine use.
The i-Factor bone graft has been used in the U.S. since 2015, Cerapedic CEO Valeska Schroeder said in the release. It is reportedly the only product of its kind that used a P-15 osteogenic cell binding peptide, and studies show it is as safe as a local autograft in single-level ACDF.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
